CA2545786A1 - Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain - Google Patents

Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain Download PDF

Info

Publication number
CA2545786A1
CA2545786A1 CA002545786A CA2545786A CA2545786A1 CA 2545786 A1 CA2545786 A1 CA 2545786A1 CA 002545786 A CA002545786 A CA 002545786A CA 2545786 A CA2545786 A CA 2545786A CA 2545786 A1 CA2545786 A1 CA 2545786A1
Authority
CA
Canada
Prior art keywords
6alkyl
effective amount
halo
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002545786A
Other languages
English (en)
French (fr)
Inventor
Jongwon Lim
Julia K. Boueres
Benito Munoz
Richard Pracitto
Nicholas Stock
Shankar Venkatraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2545786A1 publication Critical patent/CA2545786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002545786A 2003-11-21 2004-11-18 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain Abandoned CA2545786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52473403P 2003-11-21 2003-11-21
US60/524,734 2003-11-21
PCT/US2004/038669 WO2005051915A1 (en) 2003-11-21 2004-11-18 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
CA2545786A1 true CA2545786A1 (en) 2005-06-09

Family

ID=34632928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002545786A Abandoned CA2545786A1 (en) 2003-11-21 2004-11-18 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain

Country Status (7)

Country Link
US (1) US20070099950A1 (https=)
EP (1) EP1687275A4 (https=)
JP (1) JP2007512341A (https=)
CN (1) CN1882546A (https=)
AU (1) AU2004292546A1 (https=)
CA (1) CA2545786A1 (https=)
WO (1) WO2005051915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
EP1891039A1 (en) 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
JP7090344B2 (ja) * 2017-06-28 2022-06-24 国立大学法人大阪大学 セロトニン３受容体アゴニストによる疼痛の治療
CN107721925B (zh) * 2017-09-12 2020-02-14 上海交通大学 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
GB2568291A (en) * 2017-11-13 2019-05-15 Crisby Milita New use
CN114149410B (zh) * 2020-09-07 2025-02-25 四川科伦博泰生物医药股份有限公司 吡啶并环类化合物及其制备方法和用途
CN112300071B (zh) * 2020-11-25 2023-01-31 威胜生物医药(苏州)股份有限公司 一种高纯度磷酸氯喹的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077249A (en) * 1934-06-06 1937-04-13 Winthrop Chem Co Inc Basically substituted acridine compounds
US3066141A (en) * 1957-04-26 1962-11-27 Jr Ralph Jones Quinoline-type mustards and process for producing same
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
EP0446604A3 (en) * 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
FR2676228B1 (fr) * 1991-05-07 1995-01-06 Rhone Poulenc Chimie Procede de preparation de sulfate de chloroquine.
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease

Also Published As

Publication number Publication date
WO2005051915A1 (en) 2005-06-09
EP1687275A4 (en) 2009-01-14
CN1882546A (zh) 2006-12-20
JP2007512341A (ja) 2007-05-17
EP1687275A1 (en) 2006-08-09
US20070099950A1 (en) 2007-05-03
AU2004292546A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
US20070213338A1 (en) Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
RU2632900C2 (ru) Гетероциклические амины и их применение
JP6258867B2 (ja) 複素環式化合物およびその使用方法
EP3038618B1 (en) Substituted indole mcl-1 inhibitors
TWI393566B (zh) 作為週期素依賴性激酶之新穎吡唑并嘧啶
JP5033119B2 (ja) キナーゼ阻害剤としての新規アザ複素環化合物
CA2850976C (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2021523221A (ja) Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
CN114650868A (zh) Helios的小分子降解剂及其使用方法
AU2003248907B2 (en) Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
CN104606194A (zh) Pde4的双环杂芳基抑制剂
KR20150123812A (ko) 이미다조피리딘 화합물 및 이의 용도
TW200416221A (en) Compositions useful as inhibitors of ROCK and other protein kinases
JP2016512542A (ja) ピロールアミド阻害剤
CN111225913B (zh) 作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法
AU2004215658B2 (en) Novel diazabicyclic aryl derivatives
AU2007275696A1 (en) Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2022504762A (ja) Ｌｒｒｋ２の野生型および変異型の分解誘導剤
RS55377B1 (sr) Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-a
CA2545786A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
CN107466293B (zh) 杂环化合物及其应用方法
US7482457B2 (en) Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands
AU2007272830B2 (en) Alkyne-substituted pyridone compounds and methods of use

Legal Events

Date Code Title Description
FZDE Discontinued